The decision to update the pneumococcal vaccine recommendations was based on a review of evidence that demonstrated that the implementation of the 2014 recommendation had minimal impact on PCV13-type disease at the population level among older adults.
Many HMOs and insurance companies now offer ‘advice lines’ where patients can speak to an on-call nurse. In this month’s case, we look at a scenario where clinicians failed to recognize the seriousness of a patient’s complaints.
For patients with chronic obstructive pulmonary disease (COPD), inhaled corticosteroid (ICS) use was associated with an increased risk of pneumonia, according to the results of a recently published meta-analysis.
The FDA has approved the supplemental New Drug Application (sNDA) for Baxdela (delafloxacin; Melinta Therapeutics) for the treatment of community acquired bacterial pneumonia (CABP) in adult patients.
Delafloxacin may provide a feasible alternative antibiotic monotherapy option for treating patients with community-acquired bacterial pneumonia (CABP) who have renal impairment in both inpatient and outpatient settings.
Recommendations relate to diagnosis, management; recommend against routine use of Gram stain, culture
Shionogi has announced positive results from the phase 3 APEKS-NP trial of cefiderocol (S-649266) for the treatment of nosocomial pneumonia.
This slideshow reviews drug information for Xenleta. Click here for the complete Xenleta monograph.
Imipenem/relebactam/cilastatin was found to be noninferior to piperacillin/tazobactam in adult patients with hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia.
Healthcare professionals are being advised to monitor patients regularly for pulmonary symptoms indicative of ILD and/or pneumonitis, including hypoxia, cough, dyspnea, and interstitial infiltrates on radiologic exams.
